IL211842A - Antibody or human tgfbrii-binding fragment thereof, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for inhibiting angiogenesis - Google Patents
Antibody or human tgfbrii-binding fragment thereof, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for inhibiting angiogenesisInfo
- Publication number
- IL211842A IL211842A IL211842A IL21184211A IL211842A IL 211842 A IL211842 A IL 211842A IL 211842 A IL211842 A IL 211842A IL 21184211 A IL21184211 A IL 21184211A IL 211842 A IL211842 A IL 211842A
- Authority
- IL
- Israel
- Prior art keywords
- medicaments
- antibody
- manufacture
- pharmaceutical compositions
- binding fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19869708P | 2008-11-07 | 2008-11-07 | |
US17036909P | 2009-04-17 | 2009-04-17 | |
PCT/US2009/062450 WO2010053814A1 (en) | 2008-11-07 | 2009-10-29 | Anti-tgf-beta receptor ii antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
IL211842A0 IL211842A0 (en) | 2011-06-30 |
IL211842A true IL211842A (en) | 2016-09-29 |
Family
ID=41508691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL211842A IL211842A (en) | 2008-11-07 | 2011-03-21 | Antibody or human tgfbrii-binding fragment thereof, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for inhibiting angiogenesis |
Country Status (19)
Country | Link |
---|---|
US (2) | US8147834B2 (en) |
EP (1) | EP2356152A1 (en) |
JP (1) | JP5667067B2 (en) |
KR (1) | KR101283856B1 (en) |
CN (1) | CN102209727B (en) |
AR (1) | AR073909A1 (en) |
AU (1) | AU2009311375B2 (en) |
BR (1) | BRPI0921263A2 (en) |
CA (1) | CA2742961C (en) |
EA (1) | EA025169B1 (en) |
IL (1) | IL211842A (en) |
JO (1) | JO3096B1 (en) |
MX (1) | MX2011004871A (en) |
NZ (1) | NZ591943A (en) |
PA (1) | PA8846101A1 (en) |
SG (1) | SG10201401280TA (en) |
TW (1) | TWI384998B (en) |
WO (1) | WO2010053814A1 (en) |
ZA (1) | ZA201103178B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2661449B1 (en) | 2011-01-06 | 2017-03-22 | Glaxo Group Limited | Ligands that bind tgf-beta receptor ii |
AR086044A1 (en) | 2011-05-12 | 2013-11-13 | Imclone Llc | ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME |
US10828353B2 (en) | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
BR112018008867A8 (en) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | antibodies that specifically bind to pd-1 and their uses |
DK3365368T3 (en) | 2016-03-11 | 2023-06-26 | Scholar Rock Inc | TGFBETA1-BINDING IMMUNOGLOBULINS AND USE THEREOF |
AR109770A1 (en) * | 2016-10-18 | 2019-01-23 | Lilly Co Eli | TGF-b RECEIVER II ANTIBODIES |
CN106884005A (en) * | 2017-01-19 | 2017-06-23 | 樊克兴 | A kind of preparation method of colorectal cancer T cells with antigenic specificity |
CN111601616A (en) | 2017-10-24 | 2020-08-28 | 美真达治疗公司 | Compositions and methods for depleting CD117+ cells |
WO2019084053A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
US10899843B2 (en) | 2017-10-24 | 2021-01-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
CN107973853B (en) * | 2017-12-12 | 2021-04-30 | 山西农业大学 | Method for preparing Smad2 protein specific antibody by using characteristic polypeptide and application thereof |
JP2023508202A (en) * | 2019-12-24 | 2023-03-01 | メルス ナムローゼ フェンノートシャップ | TGF-βRII binding protein |
KR102314157B1 (en) * | 2020-01-10 | 2021-10-19 | 주식회사 뉴클릭스바이오 | Antibody against transforming growth factor beta receptor and uses thereof |
WO2023198194A1 (en) * | 2022-04-15 | 2023-10-19 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-cd40 antibodies and uses thereof |
CN116178567A (en) * | 2022-10-28 | 2023-05-30 | 四川大学华西医院 | Chimeric antigen receptor targeting TGF beta RII and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2136092T3 (en) * | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
DE69232986T2 (en) * | 1991-10-31 | 2003-12-11 | Whitehead Institute For Biomedical Research, Cambridge | TGF-BETA TYPE III RECEPTOR, FOR CODING CDNS AND THEIR USE |
JP2001206899A (en) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF |
JP2004121001A (en) * | 2002-08-07 | 2004-04-22 | Japan Tobacco Inc | HIGH-AFFINITY MONOCLONAL ANTIBODY TO TRANSFORMING GROWTH FACTOR-betaTYPE II RECEPTOR |
WO2007088651A1 (en) * | 2006-02-01 | 2007-08-09 | The University Of Tokyo | JOINT USE OF TGF-β SIGNAL INHIBITOR AND ANTITUMOR AGENT |
-
2009
- 2009-10-18 JO JOP/2009/0382A patent/JO3096B1/en active
- 2009-10-19 AR ARP090104017A patent/AR073909A1/en unknown
- 2009-10-19 PA PA20098846101A patent/PA8846101A1/en unknown
- 2009-10-19 TW TW098135300A patent/TWI384998B/en not_active IP Right Cessation
- 2009-10-29 SG SG10201401280TA patent/SG10201401280TA/en unknown
- 2009-10-29 NZ NZ591943A patent/NZ591943A/en not_active IP Right Cessation
- 2009-10-29 JP JP2011534731A patent/JP5667067B2/en not_active Expired - Fee Related
- 2009-10-29 AU AU2009311375A patent/AU2009311375B2/en not_active Ceased
- 2009-10-29 US US12/608,034 patent/US8147834B2/en not_active Expired - Fee Related
- 2009-10-29 KR KR1020117010399A patent/KR101283856B1/en not_active IP Right Cessation
- 2009-10-29 EA EA201170659A patent/EA025169B1/en not_active IP Right Cessation
- 2009-10-29 CN CN200980144391.1A patent/CN102209727B/en not_active Expired - Fee Related
- 2009-10-29 BR BRPI0921263-9A patent/BRPI0921263A2/en not_active IP Right Cessation
- 2009-10-29 WO PCT/US2009/062450 patent/WO2010053814A1/en active Application Filing
- 2009-10-29 MX MX2011004871A patent/MX2011004871A/en active IP Right Grant
- 2009-10-29 CA CA2742961A patent/CA2742961C/en not_active Expired - Fee Related
- 2009-10-29 EP EP09745224A patent/EP2356152A1/en not_active Withdrawn
-
2011
- 2011-03-21 IL IL211842A patent/IL211842A/en not_active IP Right Cessation
- 2011-04-29 ZA ZA2011/03178A patent/ZA201103178B/en unknown
-
2012
- 2012-02-20 US US13/400,308 patent/US20120177666A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ591943A (en) | 2012-11-30 |
PA8846101A1 (en) | 2010-06-28 |
EA201170659A1 (en) | 2011-10-31 |
TW201026326A (en) | 2010-07-16 |
KR20110067155A (en) | 2011-06-21 |
ZA201103178B (en) | 2012-10-31 |
WO2010053814A1 (en) | 2010-05-14 |
CA2742961A1 (en) | 2010-05-14 |
MX2011004871A (en) | 2011-07-13 |
EP2356152A1 (en) | 2011-08-17 |
AU2009311375A1 (en) | 2010-05-14 |
SG10201401280TA (en) | 2014-05-29 |
EA025169B1 (en) | 2016-11-30 |
US8147834B2 (en) | 2012-04-03 |
JP5667067B2 (en) | 2015-02-12 |
BRPI0921263A2 (en) | 2015-08-04 |
CA2742961C (en) | 2016-08-30 |
AU2009311375B2 (en) | 2014-07-31 |
CN102209727A (en) | 2011-10-05 |
US20100119516A1 (en) | 2010-05-13 |
AR073909A1 (en) | 2010-12-09 |
CN102209727B (en) | 2014-07-30 |
JO3096B1 (en) | 2017-03-15 |
US20120177666A1 (en) | 2012-07-12 |
KR101283856B1 (en) | 2013-07-15 |
IL211842A0 (en) | 2011-06-30 |
TWI384998B (en) | 2013-02-11 |
JP2012508170A (en) | 2012-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL211842A (en) | Antibody or human tgfbrii-binding fragment thereof, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for inhibiting angiogenesis | |
IL275854A (en) | Pharmaceutical composition and administration thereof | |
IL219876A (en) | Antibody or fragment thereof against human b7-h1, compositions comprising same and use thereof in the preparation of medicaments | |
IL233677A (en) | Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments | |
IL217490A (en) | Pyridin-4-yl derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments | |
IL206952A (en) | Aminodihydrothiazine derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments | |
IL214309A (en) | Substituted piperidines, pharmaceutical compositions comprising them and their use in the manufacture of medicaments | |
IL234166B (en) | Isoindoline compounds, pharmaceutical compositions comprising the same and use thereof in the preparation of medicaments | |
IL213019A (en) | 1-aza-3-heteroaryl-azulene derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments | |
IL198289A (en) | Substituted dihydropyrazolones, processes for their preparation, medicaments comprising them and their use for the preparation of such medicaments | |
IL222268A (en) | Substituted pyrrolo-pyridines, pharmaceutical compositions comprising them, combined compositions comprising them and their use in the manufacture of medicaments | |
IL216006A (en) | Substituted aromatic compounds, pharmaceutical compositions comprising them and use thereof in the manufacture of medications | |
IL219309A (en) | Glycoside derivatives, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for treating diabetes | |
IL212633A (en) | Monoclonal antibody or antigen-binding fragment thereof, pharmaceutical compositions comprising the same and use thereof for the manufacture of medicaments for the treatment of cancer | |
IL215065A (en) | Proline derivatives, process for their preparation, pharmaceutical compositions comprising said derivatives and use thereof for the preparation of medicaments | |
IL206296A (en) | Aminopyrazole derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for prevention or treatment of diseases | |
IL210452A (en) | Derivatives of dimethyl-oxo-dihydro-(pyridine-3 or 4-yl)- phenyl- 6- methyl-6 - phenyl -[1,3]- oxazine -2- one, pharmaceutical compositions comprising them and their use in the manufacture of medicaments | |
IL212573A (en) | Aryl methyl benzoquinazolinone compounds, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments | |
IL213517A (en) | Sulfonamide derivatives, pharmaceutical compositions comprising them and uses thereof in the manufacture of medicaments | |
IL193678A (en) | Pyrazolyl-thiophene derivatives , pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for improving cognitive function in animals | |
IL200171A (en) | Variants derived from actriib, pharmaceutical compositions comprising them and uses thereof in preparation of medicaments | |
ZA201206062B (en) | Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy | |
IL194699A (en) | Tetrahydropteridines, compositions comprising them and use thereof in the preparation of medicaments | |
IL199362A (en) | Pyridopyrimidine compounds, pharmaceutical compositions comprising them, the compounds for use as medicaments and use of the compounds in the manufacture of medicaments | |
IL207546A0 (en) | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |